Real-world use of sunitinib in Japanese patients with pancreatic neuroendocrine tumors: results from a post-marketing surveillance study

BACKGROUND: Sunitinib is approved for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNETs) in patients with unresectable, locally advanced or metastatic disease. Safety and efficacy data in Japanese patients are limited. We report outcomes from a post-marketing...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Kazuo, Toyoshima, Yasuharu, Moriyama, Shiho, Endo, Yutaka, Ito, Tetsuhide, Ohki, Emiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373178/
https://www.ncbi.nlm.nih.gov/pubmed/30413868
http://dx.doi.org/10.1007/s00280-018-3724-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373178/
https://www.ncbi.nlm.nih.gov/pubmed/30413868
http://dx.doi.org/10.1007/s00280-018-3724-3

Ejemplares similares